Oncotarget: Genomic markers of midostaurin drug sensitivity in leukemia patients

(Impact Journals LLC) Oncotarget Volume 11, Issue 29 reported that acute myeloid leukemia is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news